Crohn’s Disease vs Ulcerative Colitis: Symptoms, Diagnosis and 2025 Treatment Guidelines

Evidence reviewed: 8 November 2026. Crohn’s disease and ulcerative colitis (UC) are the two major forms of inflammatory bowel disease (IBD). Both involve chronic immune-mediated intestinal inflammation and periods of improvement and flare, but they differ in where inflammation occurs, how deeply the bowel wall is affected and which treatments are effective. These distinctions matter: oral mesalamine is an important treatment for many patients with mild ulcerative colitis, but the 2025 American College of Gastroenterology (ACG) Crohn’s guideline recommends against its use for induction or maintenance of Crohn’s remission [1,2].

What is inflammatory bowel disease?

IBD is a chronic inflammatory condition arising from an interaction between genetic susceptibility, intestinal microbes, barrier function and the immune system. The cause of any individual’s disease is not explained by a single food, stressful event or infection. IBD is not the same as irritable bowel syndrome (IBS): IBS is a disorder of gut–brain interaction without the characteristic destructive intestinal inflammation, although people with IBD may also experience IBS-like symptoms when inflammation is controlled.

IBD can affect children and adults. Symptoms and treatment risks vary with bowel location, disease activity, previous complications and other medical conditions. Appropriate care combines symptom assessment with objective markers of inflammation [1,2].

Crohn’s versus ulcerative colitis: key differences

Feature Crohn’s disease Ulcerative colitis
Location May involve any part of the gastrointestinal tract, commonly the terminal ileum and colon Involves the colon and rectum, usually extending proximally from the rectum
Distribution Skip lesions: inflamed segments separated by relatively normal bowel Classically continuous inflammation, though treatment and other circumstances can modify appearances
Depth May be transmural, involving the full bowel wall Usually concentrated in the mucosa, sometimes superficial submucosa
Typical symptoms Abdominal pain, diarrhea, weight loss, fatigue; bleeding can occur Bloody diarrhea, urgency, mucus, tenesmus and abdominal discomfort
Complications Strictures, fistulas, abscesses and malabsorption Severe colitis, toxic megacolon and colorectal cancer risk with longstanding extensive inflammation
Surgery May treat complications but does not cure the underlying condition Colectomy can remove colonic inflammation, but surgery has consequences and extraintestinal symptoms may persist

These are clinical patterns, not absolute rules. For example, an individual with Crohn’s colitis may present with bloody diarrhea, while a patient with distal UC may have urgency and surprisingly few bowel movements. A diagnosis cannot be made only from the presence or absence of blood.

Symptoms and extraintestinal manifestations

Common symptoms include persistent diarrhea, abdominal cramps, urgency, fatigue, weight loss and sometimes fever or blood in stool. Severity ranges from mild to life-threatening. Other organs may be involved:

  • Joints: peripheral arthritis or inflammatory back pain.
  • Skin: erythema nodosum or pyoderma gangrenosum.
  • Eyes: uveitis or episcleritis; painful red eyes with visual disturbance require urgent specialist assessment.
  • Liver and bile ducts: primary sclerosing cholangitis occurs more often with UC, although it can occur with other IBD types.
  • Nutrition: anemia, iron deficiency, malnutrition and bone problems, especially with active disease or prolonged steroid exposure.

Seek urgent medical care for severe abdominal pain with swelling, persistent vomiting, high fever, significant bleeding, dehydration or fainting. These may indicate severe colitis, obstruction, perforation, sepsis or an abscess.

How are Crohn’s disease and UC diagnosed?

Diagnosis combines history, examination, blood and stool investigations, endoscopy with biopsies, and imaging. Symptoms alone are insufficient. For suspected UC, the 2025 ACG guidance specifically recommends testing for Clostridioides difficile and advises against using serologic antibody panels to establish or rule out UC [2]. Other infectious colitides must also be considered.

Colonoscopy with ileal examination and biopsies can show the extent and pattern of inflammation and provide histological evidence. In suspected Crohn’s, MR enterography or intestinal ultrasound may identify small-bowel inflammation, strictures or complications not adequately assessed at colonoscopy. MRI pelvis or other imaging may help with perianal fistulas or abscesses. Capsule endoscopy is useful in selected cases after assessing the risk of capsule retention in stricturing disease [1].

What do CRP and fecal calprotectin mean?

C-reactive protein (CRP) is a blood inflammatory marker; fecal calprotectin reflects intestinal inflammation and may help distinguish active IBD from some functional symptoms. Neither test diagnoses IBD alone, and a normal CRP does not rule out active intestinal disease. Clinicians use trends in symptoms, biomarkers, endoscopy and imaging to guide treatment [1,2].

Treatment goals: remission without long-term steroids

Modern IBD care aims for durable steroid-free remission, symptom control, healing of inflammation when feasible, prevention of hospitalizations and surgery, and improved quality of life. The 2025 ACG UC guideline recommends endoscopic improvement as a management target and using fecal calprotectin to monitor treatment and possible relapse [2].

A patient can feel better while still having active mucosal inflammation; conversely, some bowel symptoms may persist after inflammatory control. This is why objective monitoring matters. There is no simple mathematical formula linking a medication dose to an individual endoscopic healing score; treatment response must be measured clinically.

Mesalamine (5-ASA): useful for UC, not routine Crohn’s disease

Mesalamine, also called mesalazine or 5-aminosalicylic acid (5-ASA), acts locally on intestinal inflammation and is a cornerstone for many patients with mild-to-moderate UC. Its formulation and route matter because they determine where drug is released:

  • Ulcerative proctitis: the 2025 ACG guideline recommends rectal mesalamine 1 g/day for induction, and rectal 5-ASA also has a role in maintenance when effective.
  • Left-sided UC: rectal mesalamine enemas can be combined with oral mesalamine for better local coverage.
  • Extensive mild-to-moderate UC: oral mesalamine at an appropriate dose is commonly recommended, with further therapy if response is inadequate [2].

Crohn’s disease is different. The 2025 ACG Crohn’s guideline recommends against oral mesalamine for inducing or maintaining remission in mildly to moderately active Crohn’s disease, because clinical efficacy is not reliably established. Automatically prescribing oral 5-ASA to everyone with IBD can therefore result in inadequate treatment of Crohn’s disease [1].

Corticosteroids: induction, not maintenance

Corticosteroids can suppress inflammation during a flare but carry risks with repeated or prolonged exposure, including infection, osteoporosis, high blood glucose, mood changes and adrenal suppression. They are not suitable long-term maintenance therapy for Crohn’s disease or UC [1,2].

Controlled ileal-release budesonide may be used for induction in selected mild-to-moderate ileocecal Crohn’s disease. The 2025 ACG guideline recommends against using it for ongoing maintenance. For UC, budesonide MMX is a different formulation targeting the colon and may be useful for inducing remission in selected mild-to-moderate disease when 5-ASA is insufficient. These formulations are not interchangeable [1,2].

More severe flares may require systemic oral or intravenous corticosteroids under specialist care, with a plan to transition promptly to an effective steroid-sparing maintenance strategy. Do not stop prolonged steroid therapy abruptly without medical advice.

Biologic and advanced therapies

People with moderate-to-severe disease, high-risk Crohn’s features, repeated steroid exposure, significant tissue damage or inadequate response to conventional therapy may benefit from advanced treatment. Selection is based on the phenotype, disease severity, prior treatment response, pregnancy plans, infection risk and local approvals and access [1,2].

Therapy class Examples and considerations
Anti-TNF biologics Infliximab and adalimumab for selected Crohn’s or UC; golimumab for UC in eligible regions. Screen for relevant infections.
Anti-integrin Vedolizumab acts relatively selectively on gut lymphocyte trafficking; used in selected Crohn’s and UC.
Interleukin-12/23 inhibition Ustekinumab is an option in eligible patients with Crohn’s or UC.
Interleukin-23 p19 inhibition Agents such as risankizumab, mirikizumab and guselkumab have disease- and jurisdiction-specific indications.
JAK inhibitors For example, upadacitinib in selected patients; requires evaluation of infections, cardiovascular events, thrombosis, malignancy and other warnings.
S1P receptor modulators Ozanimod or etrasimod are options for eligible UC patients, not routine substitutes for Crohn’s therapy.

The 2025 Crohn’s guideline suggests against forcing a patient to fail conventional therapy before starting advanced therapy when an earlier advanced approach is clinically justified [1]. The 2025 UC guidance supports multiple advanced drug classes for moderate-to-severe disease while emphasizing individualized positioning [2].

Treatment preparation commonly includes appropriate tuberculosis and hepatitis B screening, vaccination review, blood tests and discussion of infection risk and drug-specific precautions. Live vaccines or treatment interruptions may need particular planning; no single safety checklist covers every drug.

Stricturing or fistulizing Crohn’s disease

Because Crohn’s inflammation can affect the full bowel wall, strictures, fistulas and abscesses may develop. A patient with recurrent vomiting and distension may need investigation for obstruction. Perianal fistulas or abscesses often require combined gastroenterology and colorectal surgical care, imaging and sometimes drainage or seton placement. Appropriate biologic treatment may follow control of sepsis [1].

Antibiotics alone are not a definitive cure for a Crohn’s fistula, and immunosuppressive therapy should not be started in an uncontrolled abscess without proper management. Surgical intervention addresses specific complications but usually does not eliminate lifelong disease recurrence risk.

Severe ulcerative colitis and colectomy

Acute severe ulcerative colitis can cause frequent bloody stools, fever, anemia and systemic inflammation and may require hospitalization. Care generally includes stool testing to exclude important infections, intravenous corticosteroids, thrombosis prevention when appropriate, close laboratory and clinical monitoring and early colorectal surgical involvement. Selected steroid-nonresponders may require rescue therapy such as infliximab or ciclosporin, or urgent colectomy if deterioration occurs [2].

Colectomy removes the diseased colon and may eliminate colonic UC inflammation, but it is major surgery and may involve an ileostomy or an ileal pouch, with ongoing consequences and possible pouch complications. It should be described as an important treatment option, not a trivial “cure” without trade-offs.

Monitoring, nutrition and everyday care

  • Review symptoms and objective inflammation with fecal calprotectin, CRP, imaging or endoscopy as appropriate.
  • Address anemia and nutritional deficits, including iron and vitamin B12 after ileal disease or surgery when indicated.
  • Avoid smoking, particularly because it worsens Crohn’s outcomes.
  • Use NSAIDs cautiously and discuss pain treatment with clinicians when IBD is active.
  • Consider vaccinations, bone health, mental health and cancer surveillance as part of comprehensive long-term care.
  • Individualize diet: no single “IBD elimination diet” cures intestinal inflammation. Dietitian input is useful, especially for malnutrition, strictures or surgery.

Frequently asked questions

Is IBD the same as IBS?

No. IBD involves objective inflammation and may injure the bowel. IBS causes symptoms through gut–brain interaction without typical destructive IBD inflammation.

Does Crohn’s affect only the colon?

No. It may involve any part of the gastrointestinal tract, especially the ileum and colon, while UC is limited to the colon [1,2].

Is mesalamine appropriate for both diseases?

Not generally. It is effective for many mild UC presentations but is not recommended for routine induction or maintenance of Crohn’s remission [1].

Can prednisone maintain remission for years?

No. Long-term corticosteroids cause harm and are not recommended for maintenance of either condition [1,2].

Does surgery permanently cure Crohn’s?

No. It may be essential for complications but inflammatory disease can recur elsewhere or near the surgical site.

Key takeaways

Crohn’s disease and ulcerative colitis require different diagnostic and therapeutic decisions. Use biomarkers and endoscopy rather than symptoms alone, avoid long-term steroids, reserve mesalamine primarily for suitable UC, and select advanced therapy according to disease severity and individual safety.

References

  1. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2025;120:1225–1264. doi:10.14309/ajg.0000000000003465. Recommendations.
  2. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120:1187–1224. doi:10.14309/ajg.0000000000003463. Clinical summary.
  3. American College of Gastroenterology. Inflammatory bowel disease: patient overview. Accessed 8 Nov 2026.

Medical disclaimer: Educational information for general readers and healthcare learners. Suspected IBD and treatment decisions require gastroenterology evaluation. Advanced drugs, immunosuppression and steroids have significant contraindications and risks; never change them without your clinical team.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *